{"name":"Genor Biopharma Co., Ltd.","slug":"genor-biopharma-co-ltd","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":3,"colorKey":"immunology","drugs":[{"name":"GB491 combined with Letrozole","genericName":"GB491 combined with Letrozole","slug":"gb491-combined-with-letrozole","indication":"Hormone receptor-positive, HER2-negative breast cancer (presumed, based on Letrozole pairing)","status":"phase_3"},{"name":"GB491+ Fulvestrant","genericName":"GB491+ Fulvestrant","slug":"gb491-fulvestrant","indication":"Hormone receptor-positive, HER2-negative metastatic breast cancer (in combination with fulvestrant)","status":"phase_3"},{"name":"Placebo combined with Letrozole","genericName":"Placebo combined with Letrozole","slug":"placebo-combined-with-letrozole","indication":"Hormone receptor-positive breast cancer in postmenopausal women (likely adjuvant or extended therapy setting)","status":"phase_3"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":3,"colorKey":"cardiovascular","drugs":[{"name":"GB224 10mg","genericName":"GB224 10mg","slug":"gb224-10mg","indication":"Other","status":"phase_1"},{"name":"GB224 30mg","genericName":"GB224 30mg","slug":"gb224-30mg","indication":"Other","status":"phase_1"},{"name":"GB268","genericName":"GB268","slug":"gb268","indication":"Other","status":"phase_1"}]},{"name":"Metabolic","slug":"metabolic","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"GB242","genericName":"GB242","slug":"gb242","indication":"Type 2 diabetes mellitus","status":"phase_3"}]}],"pipeline":[{"name":"GB242","genericName":"GB242","slug":"gb242","phase":"phase_3","mechanism":"GB242 is a long-acting GLP-1 receptor agonist designed to improve glycemic control and promote weight loss in metabolic disorders.","indications":["Type 2 diabetes mellitus"],"catalyst":""},{"name":"GB491 combined with Letrozole","genericName":"GB491 combined with Letrozole","slug":"gb491-combined-with-letrozole","phase":"phase_3","mechanism":"GB491 combined with Letrozole works by inhibiting a molecular target (likely CDK4/6 or similar cell-cycle regulator) to arrest tumor cell proliferation, while Letrozole blocks aromatase to reduce estrogen production in hormone receptor-positive breast cancer.","indications":["Hormone receptor-positive, HER2-negative breast cancer (presumed, based on Letrozole pairing)"],"catalyst":""},{"name":"GB224 10mg","genericName":"GB224 10mg","slug":"gb224-10mg","phase":"phase_1","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"GB224 30mg","genericName":"GB224 30mg","slug":"gb224-30mg","phase":"phase_1","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"GB268","genericName":"GB268","slug":"gb268","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"GB491+ Fulvestrant","genericName":"GB491+ Fulvestrant","slug":"gb491-fulvestrant","phase":"phase_3","mechanism":"GB491 is a selective estrogen receptor degrader (SERD) that works synergistically with fulvestrant to degrade estrogen receptors and block estrogen signaling in hormone receptor-positive breast cancer cells.","indications":["Hormone receptor-positive, HER2-negative metastatic breast cancer (in combination with fulvestrant)"],"catalyst":""},{"name":"Placebo combined with Letrozole","genericName":"Placebo combined with Letrozole","slug":"placebo-combined-with-letrozole","phase":"phase_3","mechanism":"Letrozole is an aromatase inhibitor that blocks estrogen production in postmenopausal women, combined with placebo in this trial design.","indications":["Hormone receptor-positive breast cancer in postmenopausal women (likely adjuvant or extended therapy setting)"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMipwFBVV95cUxOSXpxeWZydHlDUTZXekpJQ29teFdNQjFhV1ZSakZFWm1UNU1wN3lYN0ExVTlXOXcybDNRN1IwU0FGVkwzT0tZNXJmNnl3UlhseUE4NTVLbUl0TVlFT0JYOEJLdzhtTVNSNkF0N1YyMnFMb0xXRFVMbjhoMVhsTUdDV1JUMGlac2lERGlKWFIydjM4Z1U0NTFmalU0SWtkcDAzOUdZRElnQQ?oc=5","date":"2025-06-12","type":"deal","source":"BioWorld News","summary":"Cullinan deals $712M to test Genrix bispecific TCE in autoimmune - BioWorld News","headline":"Cullinan deals $712M to test Genrix bispecific TCE in autoimmune","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqgJBVV95cUxQLUdGNExlVk1Yb25WMVhZWUlQUzgteV93WGRaSHU4WWZzMDFUYURLQXV5dFdHM3JTcERzSVQ5eUlLOFRSTXFsak8xdFJ4RmpHblB6YXJWY0tXMnhrQWluUk5OTkRqWTZvWHB0UkUyMndISW9XSS1tNDhnTDVnZmVxZm1lWUVLM3VVb2Y0dzJ2ZDExNWlhNk84RERxRkJSY2RubzhfSHZPZ3JpQ1NhSWV3ODltTlc3TF9ZWlV4LXFNWV9EdFlOT1RQNnFGeVotT3l3LWhmd2Z1Y19DcmtfQzJqdDlSaFlsZWJhWmlPMVluVkIzTmRPcTQxcDZ1UkhicGVfQUFqZ3QtZHVfTEQ1RXB4UmFkVkRmeXduUU1XQzM2YU5Jb002cnNpb01B?oc=5","date":"2024-11-28","type":"trial","source":"PR Newswire","summary":"Follicular Lymphoma Clinical Trial Pipeline Appears Robust With 50+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight - PR Newswire","headline":"Follicular Lymphoma Clinical Trial Pipeline Appears Robust With 50+ Key Pharma Companies Actively Working in the Therape","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqgFBVV95cUxNQURTaEh0VVdWTnJObHhxTUJRQUxVNFBNTkpIU3BHbjItSHFkbTBrZ3ZoUm9PNDlPc0Flc08xUG9KeVV6NmZlQ3RhMjFWZTcyblBmREpFUjZnRWpDWEs4akdmMjVnOEJIdHpOZV81SHR4YjhtRzN0NVBSVjU1c1kzZ3hDb0VIeUxta3JKNUJPQlFjem4wWnJyVUZUUjdJNUN5UTJHVXA3XzRnUQ?oc=5","date":"2024-10-31","type":"deal","source":"BioXconomy","summary":"Eddingpharm reverse-merger ‘breakthrough’ for Hong Kong stock exchange - BioXconomy","headline":"Eddingpharm reverse-merger ‘breakthrough’ for Hong Kong stock exchange","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixAFBVV95cUxQNzBfRnVhdzQwSHZkMTFSZEJGNHl2RmR2aDhiNE9XdGV0YXA5RTl1SlAwNEQ0YVlxaTV2WDJOQTNrRmxmaXNEVGo2eV9McHoyZFlsUDdvNmFyMUl4am5nUEstQkFfS216dlljbFhsVFpNMkFOMkplTURaR0dwM2NicUpHaXhOaDUyQXo4ZnQ0Vlc1enI0d19vdzl0b05xY1hFODg0M1pxOGhnTl9UYTcwdjA4VDFUOU5PTnp1YVZ4T3VRMGIz?oc=5","date":"2024-10-10","type":"pipeline","source":"Morgan Lewis","summary":"Understanding the NewCo Model: A Trending Approach of Chinese Pharmaceutical Companies - Morgan Lewis","headline":"Understanding the NewCo Model: A Trending Approach of Chinese Pharmaceutical Companies","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiowFBVV95cUxOM2JwaEphMDBkT2ZsV0VXdW5TUU5ZNmx5SVdLVTNRck4yZkVTN3VwTG9PbEJBbzlfeGk5MlVyUFVQeXV0ZmY5TEZ6OWtBTHA0MDl0ZlNsUHFrY210S3I1RFhlbU1HSTVGTXp5Mm5VUV84bnVyb01KWFY2anVfMEVhN3YzbkhhTklmUnhaczYyQWYxdUdxR3J2NVdTcnM5NjZZelpN?oc=5","date":"2024-10-08","type":"deal","source":"The Pharma Letter","summary":"Genor Biopharma announces merger with Edding in Hong Kong | Pharmaceutical | The Pharmaletter - The Pharma Letter","headline":"Genor Biopharma announces merger with Edding in Hong Kong | Pharmaceutical | The Pharmaletter","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirwNBVV95cUxQcU9XekNoNjN2SGdrUy1rZmFJZ1R2ZFpNRl83c0dKZUdqRWlYdHB2eGk4QzhrR3pwZXh4Z2pUMGFoN25acDVieFBEeGgxcEpwdXFGQkFNVDlDV2xRXzA0aXVBeVMzSVFuekhIT3RhVGdWSjN0UGM5OVU0eDd6dFBKQkNoeU5iR3pKeWRMXzlCckRNWHh3aHFVaVFVdUdjSWtqbTV5b282Y0MxN09zcWN2cm5Ma0EtWmFpRUNHUWdDNTZoVTZNb1gwdWFOUVBwcW9pYnhTVlkyRF96TVE1OHhDQlFUUzZyMEtjalEtNVdPdmFXSU9VS0pQeHBmaVAxdldBbjhHTTlwS212X0hNcUpPSXlVOFJfNndTN1VBQzV6WWRDaHc1S18yU1FUcjVPWHlLdGZLX1BfTWdJOEoySDFkbldKTjMtcEI3OTZ3el9Ra29XTUxwMHdjWVI4UjVXR2tSZk5ISWtWNHZUWGpoemtpaElDZ0VMQmdtaU5HdW51OTk0Vld0QkpCMFBCQU52cjBYYnRGVTZ0N2FtT0ZKWnRKTVowc0s3N0k2R0gtTXdyONIBrwNBVV95cUxQcU9XekNoNjN2SGdrUy1rZmFJZ1R2ZFpNRl83c0dKZUdqRWlYdHB2eGk4QzhrR3pwZXh4Z2pUMGFoN25acDVieFBEeGgxcEpwdXFGQkFNVDlDV2xRXzA0aXVBeVMzSVFuekhIT3RhVGdWSjN0UGM5OVU0eDd6dFBKQkNoeU5iR3pKeWRMXzlCckRNWHh3aHFVaVFVdUdjSWtqbTV5b282Y0MxN09zcWN2cm5Ma0EtWmFpRUNHUWdDNTZoVTZNb1gwdWFOUVBwcW9pYnhTVlkyRF96TVE1OHhDQlFUUzZyMEtjalEtNVdPdmFXSU9VS0pQeHBmaVAxdldBbjhHTTlwS212X0hNcUpPSXlVOFJfNndTN1VBQzV6WWRDaHc1S18yU1FUcjVPWHlLdGZLX1BfTWdJOEoySDFkbldKTjMtcEI3OTZ3el9Ra29XTUxwMHdjWVI4UjVXR2tSZk5ISWtWNHZUWGpoemtpaElDZ0VMQmdtaU5HdW51OTk0Vld0QkpCMFBCQU52cjBYYnRGVTZ0N2FtT0ZKWnRKTVowc0s3N0k2R0gtTXdyOA?oc=5","date":"2024-08-17","type":"patent","source":"WhaTech","summary":"Biosimilar Monoclonal Antibodies Market Uncovering Growth Opportunities in the Biosimilar Monoclonal Antibo... - WhaTech","headline":"Biosimilar Monoclonal Antibodies Market Uncovering Growth Opportunities in the Biosimilar Monoclonal Antibo...","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipwFBVV95cUxPTFZ3eWp2UEZMOWVGcU40VVo0eGhmRXg5dkg3VDBVNVJjaXgxQXdEenpablZrOTFjTnhHcVdOdGFTY0Z4b3dyM0NpdXZkVXBFSE8ySG5pMUFSeXV1b0NReVdMUTFIMzlIUXF0NFE0RnFfVWVjSzU2RkdfVlJNQXlBX1NuUUNhV2RRQzk5RmoyOGdXejFyNG56cHlxYVNkb3RXdFRBcUt2QQ?oc=5","date":"2024-08-07","type":"deal","source":"BioWorld News","summary":"Genor wins $440M+ cancer drug deal with Third Rock/Two River firm - BioWorld News","headline":"Genor wins $440M+ cancer drug deal with Third Rock/Two River firm","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2023-05-31","type":"trial","source":"GlobeNewswire","summary":"B-Cell Lymphoma Clinical Trial Pipeline Insights: - GlobeNewswire","headline":"B-Cell Lymphoma Clinical Trial Pipeline Insights:","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiekFVX3lxTE9mbVNMWDJaeDQ5a2s4YXVEQ1kyU1FSSjVUVGkxbmNaRVJKZnRFT09XSk1fd1ViaU8zbTk0NHcxbXVaTnh6ZXZud2JFSHJEUVlNaURoYUFKdmlxc2dXZDhKdm5LM01fUXdJMFZ4TzZaTnBwQjIwOWo2RmtR?oc=5","date":"2023-03-20","type":"regulatory","source":"Straits Research","summary":"Cervical Cancer Therapeutics Market Size, Demand, Report to 2033 - Straits Research","headline":"Cervical Cancer Therapeutics Market Size, Demand, Report to 2033","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi-gFBVV95cUxNZHVkZFRxdnFCWHRsT1pkQWJieEItSXN2cHp2T0kzSEszMTdJa3JBVkFqMWFjZjJUR3dycWU1b24xM0htUmpRQXRvT01pQm5aaWtRM2tCMTN6RHVtaGpVdnVpc0pNUVJ0RmRGNHF3a2huUzBRSWRzT3ZHZ1oxdjlZVFkyUGZzNmlXQlN2OVJVV3IzTmg0UmFZaXZwMkJWSjcxa2x6WHlaaFpfNzRtWFdOQW9YNjZJbjlveEN1bk1jRHo0cTFkbTdpUkd6bzlLQ2xDMFUzcEpQcERqWmxxRDhYeFp5dEFLUXNELXlsQm82MXZrOTZvQzZtS19R?oc=5","date":"2021-10-06","type":"trial","source":"GlobeNewswire","summary":"Metastatic Colorectal Cancer Pipeline Review | Clinical Trials Analysis Report 2021 | DelveInsight - GlobeNewswire","headline":"Metastatic Colorectal Cancer Pipeline Review | Clinical Trials Analysis Report 2021 | DelveInsight","sentiment":"positive"}],"patents":[],"drugCount":7,"phaseCounts":{"phase_3":4,"phase_1":3},"enrichmentLevel":0,"visitCount":3,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}